| Biomarker ID | 34 |
| PMID | 12497024 |
| Year | 2001 |
| Biomarker | Triiodothyronine |
| Biomarker Basis | Concentration Based (ng/dl) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in High Risk Group |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | High vs Moderate Risk Group |
| Type of Biomarker | Prognostic |
| Cohort | 68 men with localised prostate cncer were studied, low risk (n=24), moderate risk: (n=24), and high risk (n=20) |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.041 |
| Method Used | Chemoluminescent Assay |
| Clinical | No |
| Remarks | Low risk: serum PSA ≤10, stage≤T2a, or Gleason grade ≤ 6. These patients are treated with a radioactive implant; moderate risk: serum PSA 10-15 or Gleason 7 or ≤ T2b. These patients are treated with 3 months of combined hormonal therapy followed by an implant; high risk: Gleason > 7, tumor in seminal vesicle biopsy, serum PSA > 15 or stage T2c or T3. |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | Triiodothyronine |